Table 1.

Baseline data of the nonconcurrent (left truncated) cohort of 56,385 MHD patientsa

VariableIncident Patients(n = 23,089)Prevalent Patients(n = 33,296)
Age (yr)61.4 ± 15.660.2 ± 15.4
    >65 yr old (%)4642
Gender (% women)b4647
Diabetes (%)4744
Race and ethnicity (%)
    white4235
    black2736
    Asianc44
    Hispanicc1718
Vintage (%)
    <6 mo1000
    6 to 24 mo037
    2 to 5 yr041
    >5 yr022
Cohort time (d)339 ± 221542 ± 245
Post-HD weight (kg)c73.9 ± 20.273.6 ± 19.6
BMI (kg/m2) c26.1 ± 6.326.1 ± 6.1
Kt/V (single pool)1.51 ± 0.341.55 ± 0.30
nPCR or nPNA (g/kg per d)0.98 ± 0.251.01 ± 0.24
Serum albumin (g/dl)3.64 ± 0.453.82 ± 0.37
HCO3 (mEq/L)21.7 ± 2.921.9 ± 2.8
Phosphorus (mg/dl)5.6 ± 1.55.8 ± 1.6
Calcium (mg/dl)9.1 ± 0.79.3 ± 0.7
Urea nitrogen (mg/dl)58 ± 1760 ± 17
Creatinine (mg/dl)7.8 ± 3.19.9 ± 3.2
Potassium (mEq/L)4.7 ± 0.74.9 ± 0.7
Ferritin (ng/ml)450 ± 416725 ± 496
TIBC (mg/dl)209 ± 44197 ± 40
Blood hemoglobin (g/dl)12.2 ± 1.311.8 ± 1.2
WBC (1000 per fl)7.5 ± 2.47.2 ± 2.3
Lymphocyte (% of total WBC)21 ± 821 ± 8
Administered rHuEPO dose (units/wk)21,880 ± 23,51418,748 ± 22,044
  • a The cohort includes 36,289 (64%) patients from the first quarter (q1) and 20,096 (36%) from the subsequent quarters (q2 through q8). Patients are divided into two groups of incident (vintage < 6 mo) and prevalent (vintage > 6 mo). The P value for the difference between incident and prevalent patients for each variable is <0.001 unless specified otherwise. HD, hemodialysis; BMI, body mass index; HCO3, serum bicarbonate; nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance; TIBC, total iron binding capacity; WBC, white blood cells; rHuEPO, recombinant human erythropoietin.

  • b P value between 0.05 and 0.001.

  • c P > 0.05.